Xeris Biopharma Files 8-K Report
Ticker: XERS · Form: 8-K · Filed: Jun 3, 2025 · CIK: 1867096
| Field | Detail |
|---|---|
| Company | Xeris Biopharma Holdings, Inc. (XERS) |
| Form Type | 8-K |
| Filed Date | Jun 3, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, regulation-fd, financials
Related Tickers: XERS
TL;DR
Xeris Biopharma filed an 8-K, likely with financial updates.
AI Summary
On June 3, 2025, Xeris Biopharma Holdings, Inc. filed an 8-K report. The filing primarily concerns Regulation FD disclosures and financial statements/exhibits. No specific financial figures or material events were detailed in the provided excerpt.
Why It Matters
This filing indicates Xeris Biopharma is making disclosures required by the SEC, which could include updates on financial performance or significant business events.
Risk Assessment
Risk Level: low — The filing is a standard SEC disclosure form without immediate indication of negative events.
Key Players & Entities
- Xeris Biopharma Holdings, Inc. (company) — Registrant
- June 3, 2025 (date) — Date of earliest event reported
- 1375 West Fulton Street, Suite 1300 Chicago, Illinois 60607 (address) — Principal executive offices
FAQ
What is the primary purpose of this 8-K filing for Xeris Biopharma Holdings, Inc.?
The filing is intended to satisfy reporting obligations under Regulation FD and to include financial statements and exhibits.
What is the exact date of the earliest event reported in this filing?
The date of the earliest event reported is June 3, 2025.
Where are Xeris Biopharma Holdings, Inc.'s principal executive offices located?
The principal executive offices are located at 1375 West Fulton Street, Suite 1300, Chicago, Illinois 60607.
What is the Commission File Number for Xeris Biopharma Holdings, Inc.?
The Commission File Number is 001-40880.
What is the Standard Industrial Classification code for Xeris Biopharma Holdings, Inc.?
The Standard Industrial Classification code is 2834, which corresponds to Pharmaceutical Preparations.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 3, 2025 regarding Xeris Biopharma Holdings, Inc. (XERS).